Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Rambaldi, Andrea ^a   Jacobs, B P ^b   Iaquinto, G ^b   Gluud, C ^b  

^a Rigshospitalet   (Denmark)

^b NONE

Author keywords

*Milk thistle; Hepatitis B *drug therapy; mortality ; Hepatitis C *drug therapy; mortality ; Liver cirrhosis drug therapy; mortality ; Liver cirrhosis, alcoholic *drug therapy; mortality ; Phytotherapy *methods

Indexed keywords

PLACEBO; SILYBUM MARIANUM EXTRACT; SILYMARIN;

ALCOHOL LIVER DISEASE; ASCITES; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; EPIGASTRIC DISCOMFORT; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS C; HUMAN; IMPOTENCE; LIVER BIOPSY; LIVER CIRRHOSIS; MORTALITY; NAUSEA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SILYBUM MARIANUM; SYSTEMATIC REVIEW;

EID: 44949121637     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003620.pub3     Document Type: Review

References (146)

1. Bunout 1992 {published data only} *Bunout DB, Hirsch SB, Petermann MT, de la Maza MPC, Silva GP, Kelly MM, et al.Effects of silymarin on alcoholic liver disease. A controlled trial [Estudio controlado sobre el efecto de la silimarina en la enfermedad hepatica alcoholica]. Revista Médica de Chile 1992;120(12):1370-5.
2. Buzzelli 1993 {published data only} *Buzzelli G, Moscarella S, Giusti A, Duchini A, Marena C, Lampertico A. A pilot study on the liver protective effect of silybinphosphatidylcholine complex (IdB1016) in chronic active hepatitis. International Journal of Clinical Pharmacology, Therapy and Toxicology 1993;31(9):456-60.
3. Moscarella S, Giusti A, Marra F, Marena C, Lampertico M, Relli P, et al.Therapeutic and antilipoperoxidant effects of silybin-phosphatidylcholine complex in chronic liver disease: preliminary results. Current Therapeutic Research Clinical and Experimental 1993;53(1):98-102.
4. Buzzelli 1994 {published data only} *Buzzelli G, Moscarella S, Barbagli S, Marena C, Gentilini P. Therapeutic effect of Silipide® in patients with chronic hepatitis C non-responders (NRs) to interferon (IFN) treatment [abstract]. Journal of Hepatology 1994;21(Suppl 1):S100.
5. Fehér 1989 {published data only} Deák G, Müzes G, Láng I, Niederland V, Nékám K, Gonzalez-Cabello R, et al.Immunomodulatory effects of silymarin treatment in chronic alcoholic liver disease [Silymarin kezelés immunmoduláns hatása kronikus alkoholos májbetegségben]. Orvosi Hetilap 1990;131(24):1291-6.
6. *Fehér J, Deák G, Müzes G, Láng I, Niederland V, Nékám K, et al.Hepatoprotective activity of silymarin (Legalon®) therapy in patients with chronic alcoholic liver disease [Silymarin kezelés májvédö hatása idült alkoholos májbetegségben]. Orvosi Hetilap 1989;130:2723-7.
7. Fehér J, Lengyel G, Blázovics A. Oxidative stress in the liver and biliary tract diseases. Scandinavian Journal of Gastroenterology Supplements 1998;228:38-46.
8. Müzes G, Deák G, Láng I, Nékám K, Niederland V, Fehér J. Effects of silymarin (Legalon®) treatment on the antioxidant defense system and lipid peroxidation in patients with chronic alcoholic liver disease. A double blind study [Silymarin (Legalon®) kezelés hatása idült alkoholos májbetegek antioxidáns védörendszerére és a lipid peroxidációra (kettös vak protocoll)]. Orvosi Hetilap 1990;131(16):863-6.
9. Ferenci 1989 {published data only} Benda L, Dittrich H, Ferenci P, Frank H, Wewalka F. The influence of therapy with silymarin on the survival rate of patients with liver cirrhosis [Zur wirksamkeit von silymarin auf die überlebensrate von patienten mit leberzirrhose]. Wiener Klinische Wochenschrift 1980;92(19):678-83.
10. Ferenci P, Dragosics B, Csomos G, Schneider B. Treatment with silymarin in patients with cirrhosis of the liver - results of a controlled prospective study and of the post study surveillance [abstract]. Hepatology 1986;6(4):790.
11. *Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, et al.Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. Journal of Hepatology 1989;9:105-13.
12. Ferenci P, Dragosics B, Frank H, Benda L, Dittrich H, Meryn S. Controlled prospective study on the effects of silymarin-treatment on patients with cirrhosis of the liver [abstract]. Journal of Hepatology 1985;1(Suppl 2):S229.
13. Fintelmann 1980 {published data only} Fintelmann V, Albert A. Proof of therapeutic effect of Legalon® for toxic liver diseases in a double blind trial [Nachweis der therapeutischen wirksamkeit von Legalon® bei toxischen lebererkrankungen im doppelblindversuch]. Therapiewoche 1980;30:5589-94.
14. Lirussi 2002 {published data only} Lirussi F, Beccarello A, Zanette G, De Monte A, Donadon V, Velussi M, et al.Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent. Diabetes, Nutrition & Metabolism - Clinical & Experimental 2002;15(4):222-31. [MEDLINE: 22303308].
15. Lucena 2002 {published data only} Andrade RJ, Lucena MI, de la Cruz JP, Blanco E, Rodriguez-Mendizabal M, Rius F, et al.Effects of silymarin on the oxidative stress in patients with alcoholic liver cirrhosis. Results from a controlled, double blind, randomized pilot clinical trial [abstract]. Hepatology 1998;28(4):629A.
16. Andrade RJ, Lucena MJ, de La Cruz JP, Blanco E, Garcia-Escano MD, Alcantara R, et al.Antioxidants effects of silymarin MZ80 in patients with alcoholic liver cirrhosis: results from a randomized, placebo-controlled, double-blind, clinical trial [abstract]. Journal of Hepatology 1999;30(Suppl 1):150.
17. *Lucena MI, Andrade RJ, de la Cruz JP, Rodriguez-Mendizabal M, Blanco E, Sanchez de la Cuesta F. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study. International Journal of Clinical Pharmacology and Therapeutics 2002;40(1):2-8.
18. Láng 1990 {published data only} Fehér J, Láng I, Nékám K, Gergely P, Müzes G. In vivo effect of free radical scavenger hepatoprotective agents on superoxide dismutase (SOD) activity in patients. The Tokai Journal of Experimental and Clinical Medicine 1990;15(2,3):129-34.
19. Láng I, Deák G, Nékám K, Müzes G, Gonzáles-Cabello R, Gergely P, et al.Hepatoprotective and immunomodulatory effects of antioxidant therapy. Acta Medica Hungarica 1988;45(3-4):287-95.
20. *Láng I, Nékám K, Deák G, Müzes G, Gonzales-Cabello R, Gergely P, et al.Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers. Italian Journal of Gastroenterology 1990;22:283-7.
21. Láng I, Nekam K, González-Cabello R, Müzes G, Gergely P, Feher J. Hepatoprotective and immunological effects of antioxidant drugs. The Tokai Journal of Experimental and Clinical Medicine 1990;15(2-3):123-7.
22. Magliulo 1978 {published data only} Magliulo E, Gagliardi B, Fiori GP. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres [Zur wirkung von silymarin bei der behandlung der akuten virushepatitis, ergebnis einer an zweimedizinischen zentren durchgeführten doppelblinstudie]. Medizinsche Klinik 1978;73(28/29):1060-5.
23. Parés 1998 {published data only} Parés A, Planas R, Torres M, Caballería J, Viver JM, Acero D, et al.Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. Journal of Hepatology 1998;28(4):615-21.
24. Salmi 1982 {published data only} Salmi HA, Sarna S. Effect of silymarinon on chemical, functional, and morhological alterations of the liver: a double blind controlled study. Scandinavian Journal of Gastroenterology 1982;17:517-21.
25. Salvagnini 1985 {published data only} Salvagnini M, Martines D, Piccoli A, Sciarrone R, Rizzo A, Campesato A, et al.Silymarin treatment in alcoholic liver disease: a double blind randomized clinical trial (RCT) [abstract]. Journal of Hepatology 1985;Suppl 1:S124.
26. Trinchet 1989 {published data only} Trinchet JC, Coste T, Levy VG, Vivet F, Duchatelle V, Legendre C, et al.A randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis [Traitement de l' hépatite alcoolique par la silymarine. Une étude comparative en double insu chez 116 malades]. Gastroenterologie Clinique et Biologique 1989;13(2):120-4.
27. Velussi 1997 {published data only} *Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. Journal of Hepatology 1997;26(4):871-9.
28. Velussi M, Cernigoi AM, Viezzoli L, Dapas F, Caffau C, Zilli M. Silymarin reduces hyperinsulinemia, malondialdehyde levels, and daily insulin need in cirrhotic diabetic patients. Current Therapeutic Research Clinical and Experimental 1993;53(5):533-45.
29. Benda 1973 Benda L, Zenz W. Silymarin in liver cirrhosis [Silymarin bei leberzirrhose]. Wiener Medizinische Wochenschrift 1973;123(3):512-6.
30. Berenguer 1977 Berenguer J, Carrasco D. Double blind trial of silymarin versus placebo in the treatment of chronic hepatitis [Ensayo doble ciego de silimarina frente a placebo en el tratamiento de hepatopatias cronicas de diversa genesis]. Münchener Medizinische Wochenschrift 1977;119:240-60.
31. Berkson 1999 Berkson BM. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. Medizinische Klinik 1999;94(Suppl 3):84-9.
32. Bode 1977 *Bode JC, Schmidt U, Dürr HK. Silymarin for the treatment of acute viral hepatitis? Report of a controlled trial [Zur Behandlung der akuten virushepatitis mit silymarin]. Medizinische Klinik 1977;72(12):513-8.
33. Schmidt U, Dürr HK, Bode JC. Therapy of acute virus hepatitis with silymarin. Report of a controlled study [Zur therapie der akuten virushepatitis mit silymarin. Bericht über eine kontrollierte studie]. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin 1977;83:563-5.
34. Canini 1985 Canini F, Bartolucci L, Cristallini E, Gradoli C, Rossi A, Ribacchi R, et al.Use of silymarin in the treatment of alcoholic hepatic steatosis [L'impiego della silimarina nel trattamento della steatosi epatica alcoolica]. La Clinica Terapeutica 1985;114(4):307-14.
35. Cavalieri 1974 Cavalieri S. A controlled clinical trial of Legalon® in 40 patients [Valutazione clinica controllata del Legalon®]. Gazzetta Medica Italiana 1974;133:628-35.
36. Conti 1989 Conti M, Malandrino S, Magistretti MJ. Liver protective activity of IdB1016, a new flavanolignan complex [abstract]. 3rd International Symposium on Flavonoids in Biology and Medicine. Singapore, November 13-17: 1989:P29.
37. De Martiis 1984 *DeMartiis M, Barlattani A, Parenzi A, Sebastiani F. Relationship between changes in lipid metabolism and macrocytic anemia in chronic liver disease. Evaluation of therapy with a membranotropic drug [Rapporti tra alterazioni delmetabolismo lipidico e anemia macrocitica in corso di epatopatie croniche. Valutazione di una terapia con un farmaco membranotropo]. La Clinica Terapeutica 1984;111:135-9.
38. DeMartiis M, Fontana M, Assogna G, D'Ottavi R, D'Ottavi O. Milk thistle (Silybin marianum) derivatives in the therapy of chronic hepatopathies [I derivati del Cardomariano nella terapia delle epatopatie croniche]. La Clinica Terapeutica 1980;94(3):283-315.
39. DeMartiis M, Fontana M, Sebastiani F, Parenzi A. Silymarin, a membranotropic drug: clinical and experimental observations [La silimarina, farmaco membranotropo: osservazioni cliniche e sperimentali]. La Clinica Terapeutica 1977;81(4):333-62.
40. Dittrich 1980 Dittrich M. Double-blind study for the therapy of liver cirrhosis. Drug-Symposium Legalon, XI International Congress of Gastroenterology. Hamburg 1980.
41. Fassati 1973 Fassati P, Fassati M. Silymarin and some problems of present therapy of chronic hepatopathies [Silymarin a nekteré problémy soucasne terapie chronickych hepatopatii]. Casopis Lékasy Ceskych 1973;112:865-9.
42. Fehér 1988 Fehér J, Láng I, Nekam K, Csomos G, Müzes G, Deák G. Effect of silibinin on the activity and expression of superoxide dismutase in lymphocytes from patients with alcoholic liver disease. Free Radical Research Communications 1987;3(6):373- 7.
43. *Fehér J, Láng I, Nekam K, Müzes GY, Deák GY. Effect of free radical scavengers on superoxide dismutase (SOD) enzyme in patients with alcoholic cirrhosis. Acta Medica Hungarica 1988;45(3-4):265-76.
44. Fintelmann 1970 Fintelmann V. About silymarin therapy for fatty liver [Zur therapie der fettleber mit silymarin]. Therapiewoche 1970;23:1055-62.
45. Fintelmann 1980ex Fintelmann V, Albert A. Proof of therapeutic effect of Legalon® for toxic liver diseases in a double blind trial [Nachweis der therapeutischen wirksamkeit von Legalon® bei toxischen lebererkrankungen im doppelblindversuch]. Therapiewoche 1980;30:5589-94.
46. Flisiak 1997 *Flisiak R, Prokopowicz D. Effect of misoprostol on the course of viral hepatitis B. Hepato-Gastroenterology 1997;44(17):1419-25.
47. Flisiak R, Prokopowikz D. Effect of misoprostol on serum beta2-microglobulin in the course of viral hepatitis B. European Journal of Gastroenterology and Hepatology 1999;11(11):1227-30.
48. Flisiak R, Prokowicz D. One year follow-up of patients treated with misoprostol in acute phase of viral hepatitis B. Prostaglandins and other Lipid Mediators 2000;60(4-6):161-5.
49. Hammerl 1971 Hammerl H, Pichler O, Studlar M. On the objective assessment of silymarin action in liver diseases [Über die objektivierung der silymarinwirkung bei lebererkrankungen]. Medizinsche Klinik 1971;66(36):1204-8.
50. Ippolito 2002 Ippolito LA, Swift JM, Hershberger JM, Schmid S, Schmidt WN, Voigt MD, et al.Possible deleterious effects of milk thistle on antiviral therapy for chronic hepatitis C [abstract]. Hepatology 2002;36(4 Pt2):590A.
51. Kiesewetter 1977 Kiesewetter E, Leodolter I, Thaler H. Results of two double-blind studies on the effect of silymarine in chronic hepatitis [Ergebnisse zweier doppelblindstudien zur wirksamkeit von silymarin bei chronischer hepatitis]. Leber Magen Darm 1977;7(5):318-23.
52. Kupcová 1987 Kupcová V, Turecký L, Holomán J, Ulicná O, Brixová E, Volmut J. Therapeutic effect of silymarin in patients with cirrhosis of the liver [Terapeuticky efekt silymarinu u pacientov s cirhozou pecene]. Casopis Lékasy Ceskych 1987;126(45):1406-9.
53. Lirussi 1995 Lirussi F, Iemmolo RM, Passera D, Okolicsanyi L. Silymarin (sily) vs ursodeoxycholic acid (UDCA) in active cirrhosis: a controlled crossover study [abstract]. Journal of Hepatology 1990;11(Suppl 2):S98.
54. *Lirussi F, Nassuato G, Orlando R, Iemmolo RM, Beccarello A, Bortolato L, et al.Treatment of active cirrhosis with ursodeoxycholic acid and a free scavenger: a two year prospective study. Medical Science Research 1995;23:31-3.
55. Lirussi F, Orlando R, Iemmolo RM, Zappalà F, Nassuato G, Okolicsanyi L. Effect of UDCA and silymarin on liver function in patients with chronic active hepatitis with cirrhosis: a prospective study [abstract]. Journal of Hepatology 1989;9(Suppl 1):S184.
56. Nassuato G, Iemmolo RM, Strazzabosco M, Lirussi F, Deana R, Francesconi MA, et al.Effect of silibilin on biliary lipid composition. Experimental and clinical study. Journal of Hepatology 1991;12:290-5.
57. Loginov 1988 *Loginov AS, Matiushin BN, Sukhareva GV, Tkachev VD. Antioxidant activity of hepatotropic preparations in the treatment of chronic diseases of the liver. Terapeuticeskij Archiv 1988;60(8):74-7.
58. Muscher 1972 Muscher CH. Silymarin in chronic liver diseases [Silymarin bei chronischen erkrankungen der leber]. Therapeutische Erfahrungen 1972;111(12):1768-79.
59. Peyton 1999 Peyton BG, Spears TL, Lindsey A, Lindsey J, Sharma VK, Raufman J-P. A survey of the use of herbal medicine in patients with hepatitis C. Hepatology 1999;30(4 Pt 2):191A.
60. Pár 2000 Pár A, Roth E, Rumi G Jr, Kovács Z, Nemes J, Mózsik G. Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C [Oxidatív stressz és antioxidáns védelem alkoholos májbetegségben és krónikus C hepatitisben]. OrvosiHetilap 2000;141(30):1655-9.
61. Realini 1975 Realini S, Gonvers JJ, Hofstetter J-R. Clinical investigation of silymarin in chronic liver diseases [Essai clinique de la silymarine dans les affections chroniques du foie]. Schweizerische Rundschau fur Medizin Praxis 1975;64(19):595-8.
62. Reutter 1975 Reutter FW, Haase W. Clinical experience with silymarin for chronic liver disease [Klinische erfahrungen mit silymarin bei chronischen lebererkrankungen]. Schweizerische Rundschau fur Medizin Praxis 1975;64(36):1145-51.
63. Saba 1979 Saba P, Mignani E, Pagliai E, Guidi G, Scalabrino A, Stroppa A, et al.Efficacy of silymarin treatment for acute viral hepatitis [Efficacia del trattamento con silimarina nella epatite acuta virale]. Epatologia 1979;25(5):277-81.
64. Salmi 1982ex Salmi HA, Sarna S. Effect of silymarinon on chemical, functional, and morphological alterations of the liver: a double blind controlled study. Scandinavian Journal of Gastroenterology 1982;17:517-21.
65. Varis K, Salmi HA, Siurala M. Therapy of liver diseases with Legalon®: a controlled double-blind study [Die therapie der lebererkrankung mit Legalon®; eine kontrollierte doppelblindstudie]. Aktuelle Hepatologie. 3rd International Symposium, Cologne. Lübek: Hanseatisches Verlagskontor, November 15-17, 1978:42-3.
66. Sawaryn 1977 Sawaryn T, Szymonski K, Machalska M. Sylimarine in the treatment of chronic hepatitis [Sylimaryna w leczeniu przewleklych zapalen watroby]. Przegla epidemiologiczny 1977;31(4):445-50.
67. Schopen 1970 Schopen RD, Lange OK. Further observations on the therapy of hepatoses. Therapeutic use of silymarin [Beitrag zur therapie der hepatosen. Weitere beobachtungen zur therapeutischen anwendbarkeit von silymarin]. Die Medizinische Welt 1970;15:691-8. [MEDLINE: 72069017].
68. Schuppan 1998 Schuppan D, Strosser W, Burkard G, Walosek G. Influence of Legalon® 140 on the metabolism of collagen in patients with chronic liver disease - review by measurement of PIIINP-values [Verminderung der fibrosierungs-aktivitat durch Legalon® bei chronischen lebererkrankungen]. Zeitschrift für Allgemeinmedizin 1998;74:577-84.
69. Tanasescu 1988 *Tanasescu C, Petrea S, Baldescu R, Macarie E, Chiriloiu C, Purice S. Use of the Romanian product Silimarina® in the treatment of chronic liver diseases. Medecine Interne 1988;26(4):311-22.
70. Tkacz 1983 *Tkacz B, Dworniak D. Sylimarol in the treatment of acute viral hepatitis [Sylimarol w leczeniu ostrego wirusowego zapalenia watroby]. Wiadomosci Lekarskie 1983;36:613-6.
71. Vailati 1993 *Vailati A, Aristia L, Sozzé E, Milani F, Inglese V, Galenda P, et al.Randomized open study of the dose-effect relationship of a short course of IdB in 1016 in patients with viral or alcoholic hepatitis. Fitoterapia 1993;64(3):219-28.
72. Akriviadis 2000 Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119(6):1987-91.
73. Bindoli 1977 Bindoli A, Cavallini L, Siliprandi N. Inhibitory action of silymarin of lipid peroxide formation in rat liver mithochondria and microsomes. Biochemical Pharmacology 1977;26:2405-9.
74. Bird 1998 Bird GL, Prach AT, McMahon AD, Forrest JA, Mills PR, Danesh BJ. Randomised controlled double-blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. Journal of Hepatology 1998;28(2):194-8.
75. Boigk 1997 Boigk G, Stroedter L, Herbst H, Waldschmidt J, Rieken EO, Schuppan D. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997;26:643-9.
76. Brok 2005a Brok J, Gluud LL, Gluud C. Ribavirin plus interferon versus interferon for chronic hepatitis C. The Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD005445. DOI: 10.1002/14651858.CD005445.
77. Brok 2005b Brok J, Gluud LL, Gluud C. Ribavirin monotherapy for chronic hepatitis C. The Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD005527. DOI: 10.1002/14651858.CD005527.
78. Campos 1989 Campos R, Garrido A, Guerra R, Valenzuela A. Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetamiophen on rat liver. Planta Medica 1989;55(5): 417-9.
79. Chang 1994 Chang TT, Lin CY, Chow NH, Hsu PI, Yang CC, Lin ZZ, et al.Hepatitis B and hepatitis C virus infection among chronic alcoholic patients with liver disease in Taiwan. Journal of Formosan Medical Association 1994;93(2):128-33.
80. Christensen 1995 Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis. Gut 1995;37(1):113-8.
81. Corrao 1998a Corrao G, Zambon A, Torchio P, Arico S, La Vecchia C, di Orio F. Attributable risk for symptomatic liver cirrhosis in Italy. Collaborative Groups for the Study of Liver Diseases in Italy. Journal of Hepatology 1998;28(4):608-14.
82. Corrao 1998b Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998;27(4):914-9.
83. De Franceschi 2000 De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al.Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000;31(4):997-1004.
84. Demets 1987 Demets DL. Practical aspects inmonitoring: a brief review. Statisctics in Medicine 1987;6(7):753-60.
85. DerSimonian 1986 DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
86. Di Bisceglie 2002 Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002;36(5 Suppl 1):S121-S127.
87. Egger 1997 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315:629-34.
88. Floersheim 1978 Floersheim GL, Eberhard M, Tschumi P, Duckert F. Effects of penicillin and silymarin on liver enzymes and blood clotting factors in dogs given a boiled preparation of Amanita phalloides. Toxicology and Applied Pharmacology 1978;46(2):455-62.
89. Flora 1998 Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. The American Journal of Gastroenterology 1998;93(2):139-43.
90. Geier 1990 Geier J, Fuchs T, Wahl R. Anaphylactic shock due to an extract of Silybum marianum in a patient with immediate-type allergy to kiwi fruit [Anaphylaktischer shock durch einen mariendistel-extrakt bei soforttyp-allergie auf kiwi]. Allergologie 1990;10:S387-S388.
91. Gluud 1988 Gluud C. Testosterone and alcoholic cirrhosis. Epidemiologic, pathophyphysiologic and therapeutic studies in men. Danish Medical Bullettin 1988;35(6):564-75.
92. Gluud 1993 Gluud C, Afroudakis A, Caballeria J, Laskus T, Morgan MY, Rueff B, et al.Diagnosis and treatment of alcoholic liver disease in Europe. Gastroenterology International 1993;6(4):221-30.
93. Gluud 2001 Gluud C. Alcoholic hepatitis: no glucocorticosteroids?. Falk Symposium 121. Steatosis (NASH and ASH). Dordrecht/Boston/London: Kluwer Academic Publishers, 2001; Vol. 121:322-42.
94. Gluud 2002 Gluud C. Acute, serious drug-induced liver injury. Journal of Hepatology 2002;37:675-7.
95. Gluud 2003 Gluud C, Als-Nielsen B, D'Amico G, Gluud LL, Khan S, Klingenberg SL, et al.Hepato-Biliary Group. About The Cochrane Collaboration (Collaborative Review Groups (CRGs)) 2005, Issue 3. Art. No.: LIVER.
96. Hakova 1993 Hakova H, Misurova E. The effect of silymarin and gamma radiation on nucleid acids in rat organs. The Journal of Pharmacy and Pharmacology 1993;45:910-2.
97. Halim 1997 Halim AB, el-Ahmady O, Hassab-Allah S, Abdel-Galil F, Hafez Y, Darwish A. Biochemical effect of antioxidants on lipids and liver function in experimentally-induced liver damage. Annals of Clinical Biochemistry 1997;34(Pt 6):656-63.
98. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557- 60.
99. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & sons, Ltd.
100. ICH-GCP 1997 International Committee on Harmonization. Code of Federal Regulations & Guidelines. Vol. 1, Philadelphia, US: Barnett International/PAREXEL, 1997.
101. Ioannidis 2001 Ioannidis JP, Haidich AB, Pappa M, Pantazis N, Kokori SI, Tektonidou MG, et al.Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001;286:821-30.
102. Jacobs 2002 Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. American Journal of Medicine 2002;113(6):506-15.
103. Kjaergard 2001 Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135:982-9.
104. Kjaergard 2003 Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003;289(2):217-22.
105. Kunz 2002 Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in healthcare trials. The Cochrane Database of Methodology Reviews 2002, Issue 4. Art. No.: MR000012. DOI: 10.1002/14651858. MR000012.
106. Lawrence 2000 Mulrow C, Lawrence V, Jacobs B, Dennehy C, Sapp J, Ramirez G, et al.Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects. Evidence Report/Technology Assessment (Summary) 2000;21:1-3.
107. Liaw 2003 Liaw YF, Leung N, Guan R, Lau GK, Merican I, Asian Pacific Consensus Working Parties on Hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. Journal of Gastroenterology and Hepatology 2003;18:239-45.
108. Lieber 2000 Lieber CS. Alcoholic liver disease: new insights in pathogenesis lead to new treatments. Journal of Hepatology 2000;32(1 Suppl):113-28.
109. Lieber 2001 Lieber CS. Beneficial effects of polyenylphosphatidylcholine (PPC) in alcoholic and non-alcoholic liver injury. In: LeuschnerU, JamesO, DancygierH editor(s). Falk Symposium 121. Steatohepatitis (NASH and ASH). Vol. 121, Dordrecht/Boston/London: Kluwer Academic Publishers, 2001:345-61.
110. Lieber 2003a Lieber CS, Leo MA, Cao Q, Ren C, DeCarli L. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. Journal of Clinical Gastroenterology 2003;37:336-9.
111. Lieber 2003b Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S, for the Veterans Affairs Cooperative Study 391 Group. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcoholism, Clinical and Experimental Research 2003;27(11):1765-72.
112. Lok 2001 Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34(6):1225-41.
113. Luper 1998 Luper S. A review of plants used in the treatment of liver disease: part 1. Alternative Medicine Review 1998;3(6):410- 21.
114. Main 1998 Main J, McCarron B, Thomas HC. Treatment of chronic viral hepatitis. Antiviral Chemistry and Chemotherapy 1998;9(6):449-60.
115. Marbet 1987 Marbet UA, Bianchi L, Meury U, Stalder GA. Long-term histological evaluation of the natural history and prognostic factors of alcoholic liver disease. Journal of Hepatology 1987;4(3):364-72.
116. Mato 1999 Mato JM, Cámara J, Fernández de Paz J, Caballería L, Coll S, Caballero A, et al.S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Journal of Hepatology 1999;30:1081-9.
117. Mezey 1991 Mezey E, Caballeria J, Mitchell MC, Pares A, Herlong HF, Rodes J. Effect of parenteral amino acid supplementation in severe alcoholic hepatitis: a randomised controlled trial. Hepatology 1991;14(6):1090-6.
118. Moher 1998 Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher R, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-anlyses. Lancet 1998;352:609-13.
119. Morgan 1999 Morgan MY. Alcoholic liver disease: natural history, diagnosis, clinical features, management, prognosis and prevention. In: BircherJ, BenhamouJ-P, McIntyreN, RizzettoM, RodésJ editor(s). Oxford Text Book of Clinical Hepatology. Second Edition. Vol. 2, Oxford: Oxford University Press, 1999:1185-238.
120. Muriel 1992 Muriel P, Garciapina T, Perez Alvarez V, Mourelle M. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. Journal of Applied Toxicology 1992;12:439-42.
121. Pelletier 2003 Pelletier G, Roulot D, Davion T, Masliah C, Causse X, Oberti F, et al.A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice. Hepatology 2003;37:887-92.
122. Pianko 2000 Pianko S, McHutchison JP. Treatment of hepatitis C with interferon and ribavirin. Journal of Gastroenterology and Hepatology 2000;15(6):581-6.
123. Powell 1968 Powell WJ Jr, Klatskin G. Duration of survival with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general managment of the disease. American Journal of Medicine 1968;44(3):406-20.
124. Poynard 1994 Poynard T, Barthelemy P, Fratte S, Boudjema K, Doffoel M, Vanlemmens C. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis by a case control study and simulated controls. Lancet 1994;344(8921):502-7.
125. Rambaldi 2001a Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver cirrhosis and fibrosis. The Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD002148. DOI: 10.1002/14651858.CD002148.pub2.
126. Rambaldi 2001b Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. The Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD002235. DOI: 10.1002/14651858.CD002235.
127. Rambaldi 2002a Rambaldi A, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease - a Cochrane Review. The American Journal of Gastroenterology 2002;97(7):1674-81.
128. Rambaldi 2002b Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease - Cochrane Review. Liver 2002;21:398-404.
129. Rambaldi 2003 Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. The Cochrane Database of Systematic Reviews 2005, Issue 2. Art.No.: CD003620. DOI: 10.1002/14651858.CD003620.pub2.
130. Ramellini 1974 Ramellini G, Meldolesi J. Stabilization of isolated rat liver plasma membranes by treatment in vitro with silymarin. Arzneimittel Forschung 1974;24(5):806-8.
131. Rauen 1971 Rauen HM, Schriewer H. The antihepatotoxic effect of silymarin on liver damage induced by carbon tetrachloride, d-galactosamine, and allyl alcohol [Die antihepatotoxische wirkung von silymarin bei experimentellen leberschädigunug der ratte durch tetrachlorkohlenstoff, D-galaktosamin und allylalkohol]. Arzneimittel Forschung 1971;21:1194-212.
132. Rauen 1973 Rauen HM, Schriewer H. The antihepatotoxic effect of parenteral silymarin liver injury caused by CCL4 in the rat [Die antihepatotoxische wirkung von parenteral verabreichten silymarin bei der leberbeschädigung der ratte durch carboniumtetrachloride (CCL4)]. Arzneimittel Forschung 1973;23:148-9.
133. Rubin 1968 Rubin E, Lieber CS. Alcohol-induced hepatic injury in non-alcoholic volunteers. New England Journal of Medicine 1968;278(16):869-76.
134. Russo 2000 Russo F, Bacosi, Miglioresi L, Ricci GL. Leucopenia is a side effect of combination therapy for hepatitis C infection. The American Journal of Gastroenterology 2000;95(4):1100-1.
135. Saller 2001 Saller R, Meier R, Brignoli R. The use of sillymarin in the treatment of liver diseases. Drugs 2001;61:2035-63.
136. Schriewer 1973 Schriewer H, Badde R, Roth G, Rauen HM. The anti-hepatoxic effect of silymarin on thioacetamide-induced liver-damage. Arzneimittelforschung 1973;23:160.
137. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methological quality associated with estimates of treatment effects in controlled trials. Journal of American Medical Association 1995;273(5):408-12.
138. Szilard 1988 Szilard S, Szentgyorgyi D, Demeter I. Protective effect of Legalon in workers exposed to organic solvent. Acta Medica Hungarica 1988;45(2):249-56. [MEDLINE: 3073356].
139. Sørensen 1984 Sørensen TIA, Orholm M, Bentsen KD, Høybye G, Eghøje K, Christoffersen P. Prospective evaluation of alcohol abuse and alcoholic liver injury in as predictors of developement of cirrhosis. Lancet 1984;2(8397):241-4.
140. Tanasescu 1988 Tanasescu C, Petrea S, Baldescu R, Macarie E, Chiriloiu C, Purice S. Use of the Romanian product Silimarina® in the treatment of chronic liver diseases. Medecine Interne 1988;26(4):311-22.
141. Trinchet 1992 Trinchet JC, Balkau B, Poupon RE, Heintzmann F, Callard P, Gotheil C, et al.Treatment of severe alcoholic hepatitis by infusion of insulin/glucagon: a multicenter sequential trial. Hepatology 1992;15(1):76-81.
142. Tuchweber 1979 Tuchweber B, Sieck R, Trost W. Prevention of silybin of phalloidin-induced acute hepatotoxicity. Toxicology and Applied Pharmacology 1979;51:265-75.
143. Valenzuela 1985 Valenzuela A, Barria T, Guerra R, Garrido A. Inhibitory effect of the flavonoid silymarin on the erythrocyte hemolysis induced by phenylhydrazine. Biochemical and Biophysical Research Communications 1985;126:712-5.
144. Vickers 1998 Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. Controlled Clinical Trials 1998;19(2):159-66.
145. Zavaglia 2000 Zavaglia C, Airoldi A, Pinzello G. Antiviral therapy of HBV - and HCV induced liver cirrhosis. Journal of Clinical Gastroenterology 2000;30(3):234-41.
146. Rambaldi 2005 Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases - a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. American Journal of Gastroenterology 2005;100(11):2583-91.